Cor.4U Mel.Cor Human Cardiomyocyte MEA Assay Service

Cells Cor.4U® Human iPS derived cardiomyocytes
Species Human
Cell Source Induced pluripotent stem (iPS) cells (caucasian)
Cell Format Monolayer of pure cardiomyocytes
Service Content       Electrophysiological analysis
Delivery A study protocol will be sent to initiate the study.
Timeline Draft report: within 4 weeks.
  This email address is being protected from spambots. You need JavaScript enabled to view it.

Human Cor.4U® Mel.Cor® is an in vitro and non-invasive assay system to monitor Axiogenesis' Cor.4U® human induced pluripotent stem (iPS) cell-derived cardiomyocytes by means of extracellular field potential recordings from microelectrode arrays (MEA).

The Cor.4U® human iPS cell-derived cardiomyocytes reveal electrophysiological properties typical for human cardiac myocytes like functional Na+, Ca2+, and K+ voltage-gated ion channels including the hERG channel and their correct modulation through e.g. ß-adrenergic or muscarinic receptors.

The combination of the Cor.4U® human cardiomycoytes with the Mel.Cor® MEA assay provides an ideal tool to assess pharmacological, safety pharmacological and toxicological effects of drug candidates on human cardiomyocytes.

Effects of substances from different compound classes tested:

Compound class

Drug

(application)

Effect conc. (µM)

hSC-CM

IKr blocker

 

E-4031

(Class III antiarhythmic)

10 nMfAPD+

250 nM; IB

Cisapride

(Prokinetic)

100 nM; fAPD+

1 µM; IB

Dofetilide

(Class III antiarhythmic)

10 nM, fAPD+

INa blocker

Tetrodotoxin (TTX)

(Neurotoxin)

1 - 10 µM; NC and SD+

ICa,L blocker

Nifedipine

(Anti-hypertensive)

100 nM; fAPD-

1000 nM; BA

Verapamil

(Anti-hypertensive)

0.1 µM fAPD-

1- 10 µM BA

ß-adrenergic receptor agonist

Isoproterenol

(Bronchodilator)

1 - 10 nM; PC

α-adreneric  

receptor agonist

Phenylephrine

(Vasoconstrictor)

100 nM; PC

Table 1: Abbreviations: NC - negative chronotropic, PC - positive chronortropic, fAPD+ - fAPD prolongation, fAPD- -fAPD shortening, IB - irregular beating, BA - beating arrest, SD+ - slope duration prolongation

 

Advantages Cor.4U MEA

  • Primary-like cardiomyocytes of human origin.
  • Non-invasive test system.
  • Predictive and relevant for cardiac safety pharmacology.
  • Low amount of compound required.

FIND US

Nattermannallee 1, Bldg S20
50829 Cologne
Germany –  (Map)

600 W Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
USA – (Map)

EMAIL US

Orders: order@axiogenesis.com
Support: support@axiogenesis.com
Other: office@axiogenesis.com

FOLLOW US

Twitter:  |   LinkedIn:  |   Newsletter:  Subscribe Axiogenesis Newsletter

CALL US

Phone (Main)
+49 221 99 88 18-0

Phone (US)
+1 844-511-6959

Fax + 49 221 99 88 18-10